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Recommended standards for analyzing and reporting on lower extremity ischemia were 
first published by the Journal of Vascular Surgery in 19861 after approval by the Joint 
Council of The Society for Vascular Surgery and the North American Chapter of the 
International Society for Cardiovascular Surgery. Many of these standards have been 
accepted and are used in the current literature on peripheral arterial occlusive disease. 
With the passage of time, some oversights, aspects that require clarification, and bettet 
modifications have been recognized. This report attempts to correct hese shortcomings 
while reinforcing those recornmendations that have proven satisfactory. Explanatory 
eomments are added to facilitate understanding and application. This version is intended 
to replace the original version. (J Vasc Surg 1997;26:517-38.) 
DEF IN IT IONS AND CLASS IF ICAT ION 
CRITERIA  
The progression of disease in a chronically isch- 
emic extremity may occur in a stepwise fashion, with 
each step representing an acute occlusive event. 
Therefore, reports that deal with the management of
lower extremity ischemia should not mix these, or 
other acute ischemic episodes, with chronic ischemic 
stares, because the r sults of emergency and elective 
interventions for the two are influenced by different 
variables and are not comparable. Furthermore, dif- 
ferent classification criteria should be used for acute 
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and chronic ischemia when attempting tos t raß  limbs 
according to severity of ischemia. 
Acute ischemia 
The following categories for stratifying levels of 
severity of acute limb ischemia are recommended 
(Table I). 
II. 
"Viable": not immediately threatened; no con- 
tinuing ischemic pain, no neurologic deficit, 
skin capillary circulation adequate; clearly audi- 
ble Doppler arterial flow signals in a pedal ar- 
tery. 
"Threatened" viability: implies reversible isch- 
emia in a limb that is salvageable without major 
amputation if  arterial obstruction is relieved 
quickly. Two levels within this category are rec- 
ognized for therapeutic purposes, and their 
differences are tabulated in Table I: IIa--mar- 
ginally threatened and IIb--immediately threat- 
ened. Neither category has clearly andible 
Doppler signals in pedal arteries. Patients who 
have marginally threatened extremities (IIa) 
may experience numbness and have transient or 
minimal sensory loss, limited to the toes. Con- 
tinuous pain is absent. In contrast, immediately 
517 
JOURNAL OF VASCULAR SURGERY 
518 Rutherford et al. September 1997 
Table I. Clinical categories of acute limb ischemia 
Category Description/prognosis 
Findings 
Sensory loss 
Doppler signals 
Muscle weakness Arterial Venous 
I. Viable 
II. Threatened 
a. Marginally 
b. Immediately 
III. Irreversible 
Not immediately threatened 
Salvageable if promptly 
treated 
Salvageable with immediate 
revascularization 
Major tissue loss or 
permanent erve damage 
inevitables 
None 
Minimal (toes) or none 
More than toes, associated 
with rest pain 
Profound, anesthetic 
None Audible Audible 
None Inaudible Audible 
Mild, moderate Inaudible Audible 
Profound, paralysis (rigor) Inaudible Inaudible 
threatened (IIb) limbs have persistent ischemic 
rest pain, detectable oss of sensation above the 
toes or a continuing lack of all sensation in the 
toes, and/or any motor loss (paresis or paraly- 
sis). 
III. Major, "irreversible" ischemic hange: predict- 
ably will require major amputation or suffer sig- 
nificant, permanent neuromuscular damage re- 
gardless of therapy. Profound sensory loss and 
muscle paralysis extending above the foot, ab- 
sent capillary skin flow distally, or evidence of 
more advanced ischemia (e.g., muscle rigor or 
skin marbling) are present. Neither arterial nor 
venous flow signals are andible over pedal ves- 
sels. 
COMMENT: Temporal criteria (e.g., 6 to 12 
hours ofischemia) are not included in these report- 
ing standards because the event oftissue damage also 
depends on location of occlusion, existing collateral 
circulation, and other factors. More definitive tests of 
tissue viability are still needed. At this time, "revers- 
ibility" of ischemia or "salvageability" of the foot or 
limb cannot always be accurately predicted eren by 
those with considerable clinical experience. The orig- 
inal grouping ofpatients into "viable," threatened," 
and "irreversible" categories was thought o be of 
value not only in comparing the results of treatment 
but in determining appropriate therapy. Its intent 
was to separate patients into those, at one extreme, 
who were clearly viable, in whom there was time for 
deliberate, detailed evaluation, and in whom inter- 
vention might not even be ultimately required, and 
those, at the other extreme, who would inevitably 
suffer major tissue loss (amputation) or permanent 
ischemic nerve or muscle damage, such that the goal 
of a painless, functional limb could not be achieved 
regardless of the rapidity and extent of revasculariza- 
tion. This left an intermediate (threatened) group of 
patients who required prompt revascularization to
achieve limb salvage and usually needed to be taken 
directly to the operating room without preliminary 
angiography and with a minimum of diagnostic stud- 
ies. Were it not for advances in thrombolytic therapy, 
and some misinterpretation f the original scheme, 
these three basic categories might still sutfice, even if 
not infallibly predictive of outcome. The original 
criteria for a viable limb included "ankle pressure 
above 30 mm Hg" in addition to audible Doppler 
flow signals in pedal arteries, as originally suggested 
by Lavenson et al. 2 Unfortunately, some investiga- 
tors focused more on this level of ankle pressure (30 
mm Hg) than on audible arterial flow signals and 
other more important criteria in separating catego- 
ries I and I I?  A four-level modification of the origi- 
nal SVS/ISCVS scheme was ultimately proposed for 
stratifying patients with thrombosed native arteries 
and arterial grafts, using a 30 mm Hg ankle pressure 
to separate the first two levels ofacute ischemia? The 
reported results with more severe levels of ischemia 
using this scheme clearly did not fit with the intent or 
reality of the SVS/ISCVS scheme, claiming success 
with lytic therapy in the majority ofthose classified as 
"irreversible"! It seems apparent from this and other 
reports of the results of thrombolytic therapy that 
many cases were included that were not truly "acute" 
in the usual surgical sense. Furthermore, the concept 
of what can be considered acute limb ischemia has 
clearly been stretched in recent prospective random- 
ized trials of thrombolytic therapy compared with 
surgery. For example, in the STILE trial the vast 
majority of cases were more than 14 days after arte- 
rial thrombosis. 4 Nevertheless, it has become vident 
that there is a subgroup of patients whose limb via- 
bility was originally defined as being "threatened" 
(typically those who had no audible Doppler pedal 
artery signals but only mild or evanescent sensory 
loss) in whom limb salvage could be achieved with a 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 3 Rutherford et el. 519 
Table II .  Clinical categories of chronic limb ischemia* 
Grade Category Clinical description Objective criteria 
0 0 Asymptomatic--no hemodynamically Normal treadmill or reactive hyperemia test 
significant occlusive disease 
1 Mild claudication 
I 2 
3 
II* 4 
III* 5 
Moderate claudication 
Severe claudication 
Ischemic rest pain 
Minor tissue loss--nonhealing ulcer, 
focal gangrene with diffuse pedal 
ischemia 
6 Major tissue loss--extending above TM Same as category 5
level, functional foot no longer 
salvageable 
Completes treadmill exerciser; AP after exercise >50 mm Hg 
but at least 20 mm Hg lower than resting value 
Between categories 1 and 3 
Cannot complete standard treadmill exerciseJ" and AP after 
exercise <50 mm Hg 
Resting AP <40 mm Hg, fiat or barely pulsatile ankle or
metatarsal PVR; TP <30 mm Hg 
Resting AP <60 mm Hg, ankle or metatarsal PVR fiat or 
barely pulsatile; TP <40 mm Hg 
AP, An]de pressure; PVR, pulse volume recording; TP, toe pressure; TM, transmetatarsal. 
*Grades II and III, categories 4, 5, and 6~ are embraced by the term chronic critical ischemia. 
{Five minutes at 2 mph on a 12% incline. 
more time-consuming approach, for example, cathe- 
ter-directed thrombolytic therapy. This created a 
weakness in our original scheme, especially now that 
improved catheter-directed techniques and high- 
dose protocols can achieve improved per fusion in 
one third to one half of the time formerly required 
for lytic therapy. Therefore, we have subdivided cat- 
egory II into two levels, with the implication that 
there is time in level 2a patients for angiography or 
some other needed studies before embarldng on the 
most appropriate r vascularization procedure, as long 
as close surveillance is maintained. In level 2b, imme- 
diate revascularization is required. This change 
should help clarify reports of treatment outcome in 
this intermediate l vel of acute limb ischemia. 
Finally, it is recommended that cases of arterial 
thrombosis and embolism not be mixed together or, 
if they are combined, the distribution of cases into 
these categories hould be clearly stated. Cases of 
atherothrombotic microembolism ("blue toe syn- 
drome") usually have transient focal ischemia, occa- 
sionally with minor tissue loss, but without diffuse 
forefoot ischemia. Therefore, they should either be 
not included in reported experiences ofacute arterial 
thromboembolism or placed in category I (viable). 
As discussed further below, the practice of including 
such cases of transient focal ischemia in with cases of 
chronic critical ischemia is also inappropriate. 
Chronic ischemia 
A suggested classification for grading the severity 
of chronic arterial occlusive disease for the purposes 
of standardized reporting practices i  outlined in Ta- 
ble II. Symptomatic disease is stratified into six cate- 
gories to provide the greater breadth required for 
many clinical research reports. Thus categorical c in- 
ical improvement (discussed later) is made possible 
within the broad heading of claudication by subdi- 
viding it into three levels, and gangrene is divided 
into two levels according to its extent and the possi- 
bility of salvaging a functional foot remnant. Simpler 
broader gradations, based on Fontaine's original 
clinical staging, are offered in parallel. In both, a zero 
category or grade has been used to identify those 
who have no symptoms, or merely sensations of 
coldness and either no clinical signs of occlusive 
disease or modest pulse diminution. Such a category 
or grade is valuable because it also allows postopera- 
tive improvement to be gauged at all levels. It is also 
in keeping with the practice of assigning "zero" to 
asymptomatic stages of disease in SVS/ISCVS re- 
porting standards. However, this results in different 
numbers being assigned to the Fontaine-equivalent 
grades than has been common practice in Europe. 
Also, although it has become common practice in 
Europe to divide patients with claudication (grade I) 
into two levels (Fontaine stages IIa and IIb) to indi- 
cate disability, such an imprecise separation is not 
recommended here. 
Before discussing the criteria for classification of 
chronic ischemia, a number of terms require defini- 
tion and clarification. 
Claudication means extremity pain, discomfort, 
or weakness that is consistently produced by the 
same amount of walking or equivalent muscular ac- 
tivity in a given patient and that is promptly relieved 
by cessation of that activity. Ordinarily, claudication 
implies ischemic muscle pain induced by exercise, 
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and as such may be identified as hip, buttock, thigh, 
or calf claudication. The severity of claudication can 
be reliably related to time and distance walked only if 
speed and incline grade are also standardized. The 
speed, incline, and time recommended here are fairly 
standard for routine studies in North American vas- 
cular diagnostic laboratories. However, for clinical 
trials such a constant loäd protocol may not be as 
appropriate as a graded load protocol in which the 
incline is increased at timed intervals. 4 The latter 
protocol appears to have better reproducibility and 
minimal placebo effect. Only when standardized pro- 
tocols are used can the effects of treatment be accu- 
rately assessed and different therapies compared. 5 
Qualifying candidates for therapeutic interven- 
tion as "disabled" patients with claudication or with 
"less than one block" claudication is convenient, and 
adequate for some clinical practices, hut not precise 
enough for categorizing patients in clinical research 
studies or trials. Disability is relative, being related to 
activity levels governed by age, occupation, and avo- 
cational interests. Disability is better gauged by a 
more comprehensive analysis of activities and capa- 
bilities, such as community-related activity or walk- 
ing impairment questionnaires or other similar quality 
of life instnlments. 6 Therefore, "disabling" daudica- 
tion, although an acceptable indication for interven- 
tion in carefully selected patients, is no more accept- 
able as a categorizing criterion than "less than x 
blocks claudication distance." Either the broad grade 
of intermittent clandication (grade I or Fontaine 
grade II) should be used, or objective and reproduc- 
ible criteria for further stratification must be used, for 
example, using the categorical criteria recommended 
in Table II. However, stratifying patients by walldng 
distances using a standardized treadmill protocol is 
appropriate for therapeutic linical trials, and here 
either initial claudication distance (ICD; distance 
before onset of pain) or absolute walking distance 
(ACD; distance at which patient is forced to stop 
bccause of pain) should be specified. Thus patients 
with claudication need further separation only for the 
comparative purposes of clinical investigation. 
Resting ankle systolic pressure measurements 
alone will not cleanly separate patients with claudica- 
tion according to degree of symptom severity, al- 
though it has been shown that those in the lower 
range of resting anlde-brachial index (ABI) or anldc 
pressure clearly have a worse prognosis. 7-12 The non- 
invasive vascular laboratory test criteria recom- 
mended in Table II were chosen to reprcsent first the 
minimum acceptable objective vidence of claudica- 
tion, designated as "mild." Then the categories of 
"moderate" and "severe" were further defined by 
whether the patient could complcte 5minutes on the 
treadmill at a standard speed and incline. A reduction 
in ankle pressure after this exercise to 50 mm Hg or 
less was also required in the latter two categories to 
confirm that ischemia was responsible for the limit- 
ing pain. Claudication may be experienced without 
the ankle pressure being reduced to this level, but it is 
usually "mild." Thus ifthe duration of ambulation is
less than 5 minutes or if the patient can only ambu- 
late for 5 minutes by reducing treadmill speed or 
incline, the patient qualifies as having severe claudica- 
tion. In testing patients with claudication, Wilbur 
and Olcott 13 have shown that the ankle pressures 
obtained i minute after a 5-minute treadmill exercise 
are roughly equivalent to those obtained 30 seconds 
after the lesser degree of hyperemia induced by an 
equal duration of suprasystolic thigh cuff occlusion. 
Repeated orsiflexion of an elevated limb was signif- 
icantly less effective than either in producing a prcs- 
sure drop. Therefore, the former two are acceptable 
as equivalent stress tests, although treadmill exercise 
is preferred. Walking for 5 minutes at a trcadmill 
speed of 2 mph ( 176 fr/min) is roughly equivalent to 
walking three blocks (900 ft) at average speed. 
The term "ischemic restpain" has becn well char- 
acterized by Cranley 14 and indicates diffuse pedal 
ischemia. It is a severe pain not readily controlled by 
analgesics that is localized to the forefoot and toes 
or, if more proximal, includes these distal parts. It 
may also be localized to the vicinity of focal ischemic 
lesions. It is brought on or made worse by elevation 
and relieved by dependency and therefore is often 
only experienced at night or when lying down. Dif- 
fuse pedal ischemia with ischemic rest pain is com- 
monly associated with anlde pressures lower than 40 
mm Hg and toe pressures lower than 30 mm Hg. 
"Gangrene" may be focal, as in the case of focal 
arterial thrombosis or atherothrombotic microem- 
bolism, where there is still adequate perfusion of 
adjacent issues to allow successful auto- or local 
surgical amputation. Such focal gangrene may there- 
fore not be associated with diffuse pedal ischemia nd 
ischemic rest pain. Gangrene associated with diffuse 
pedal ischemia will not allow successful management 
by local measures alone (i.e., will at least require 
pharmacotherapy and usually a revascularization pro- 
cedure to allow debridement/amputation o heal) 
and is almost invariably associated with typical isch- 
emic rest pain. 
Ulcers in distal parts of the extremity may be 
caused or perpetuated by a number of etiologic fac- 
tors, each with its own distinguishing characteristics 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 3 Rutherford et al. 521 
(e.g., pressure, venous insufficiency, trauma, dia- 
betic, or other neuropathies), asweil as by persistent 
arterial insufläciency. The term "nonhealing ischemic 
ulcer" implies that, regardless ofinitial cause, there is 
insufficient arterial perfusion to support he inflam- 
matory response required for healing. Associated 
with this, there is usually ischemic rest pain and 
objective vidence of diffuse pedal ischemia, for ex- 
ample, critical reductions in the ankle or toe pres- 
sures, a flat or barely pulsatile plethysmographic trac- 
ing at the anlde or transmetatarsal level, a reduced 
cutaneous oxygen level, or the lack of an inflamma- 
tory response as gauged by radionuclidc studies, ls-19 
An anlde pressure upper limit ofó0 mm Hg is recom- 
mended for this category rather than 40 mm Hg. 
Similarly, a toe pressure of 40 mm Hg is recom- 
mended for this category, instead of the 30 mm Hg 
suggested for rest pain. These higher pressures rec- 
ognize the additional perfusion that is required to 
heal an ulcer or a distal amputation, especially if 
secondary infection is present. The other tests men- 
tioned above may be useful to gange local healing, 
particularly in patients with diabetes in whom anlde 
pressures may be unreliable or absent, or when le- 
sions on the greät oe preclude toe pressure measure- 
ment. However, they have either have too wide a 
range of values for predicting healing or have not 
been correlated predictably with ischemic rest pain. 
For example, a TcO2 of 30 mm Hg is conveniently 
equivalent to a toe pressure of 30 mm Hg in predict- 
ing healing, but there is a significant range between 
no healing (<20 mm Hg) and reliable prediction of 
healing (>40 mm Hg), and it has not been weil 
correlated with the onset of rest pain. Therefore, 
neither it nor the other tests are currently recom- 
mended as a stand-alone criteria for categorizing 
levels of chronic ischemia. 
COMMENT: The pressure levels selected above 
are admittedly arbitrary, and it is recognized that no 
single level can cleanly separate categories, but they 
have a rauonal basis. The European Consensus on 
Critical Ischemia 2° selected a common pressure level 
(50 mm Hg ankle and 30 mm Hg toe pressure) to 
define both Fontaine classes III and IV, equivalent to 
our grades II and III and categories 4, 5, and 6 
inclusively. Using the same criteria both for those 
with rest pain and for those with tissue loss may be 
simpler, but it does not recognize the difference 
between the level of perfusion pressure required to 
preserve intact tissue and stave oft ischemic rest pain 
on the one hand and the addiuonal circulatory re- 
quirement for healing ischemic foot lesions on the 
other. 
Others have recommended anABI rather than an 
ankle pressure to define these advanced levels of 
ischemia. However, absolute pressure levels are bet- 
ter for defining levels ofchronic ischemia because it is 
the actual perfusion pressure that is critical. A given 
ABI can represent a wide range ofanlde pressures, for 
example, the difference in ankle pressure between 
two patients with an ABI of 0.30 but with systolic 
blood pressures of 110 and 160 is 15 mm Hg (33 
mm Hg compared with 48 mm Hg), an almost 50% 
difference, with a likelihood of ischemic pain only in 
the former. However, pressure indexes such as the 
ABI are better for comparing roups of patients, as 
weil as monitoring a given patient over different 
points in time, for example, after bypass urgery. 
The term «limb salvage" is a misnomer and orten 
loosely applied. It is commonly applied to indicate 
salvage of the foot, not the limb, and this is retro- 
spectively determined, yet the term is often applied 
prospectively. It might be best abandoned, but clini- 
cians are likely to continue to use it. "Chronic critical 
ischemia," as first defined by Jamieson et al)s and as 
dcveloped by a European Consensus Group chaired 
by Dormandy, 2° is a more apt term. The presence of 
rest pain, nonhealing ulceration, or gangrene plus 
objective evidence of  diffuse pedal ischemia, as de- 
fined earlier (i.e. grades II and III and categories 4, 
5, and ó in Table II), qualify the patient for such 
categorization. Rest pain, in the absence of frank 
tissue loss, should persist at a level that requires 
moderate to strong analgesia for at least 3 weeks 
before such designation. 
The term chronic "subcritical" ischemia has been 
suggested for a particular subgroup that falls be- 
tween the definitions of claudication and chronic 
critical ischemia. Typically, these patients have levels 
of perfusion pressure between that required for heal- 
ing (e.g., 60 mm Hg) and that commonly associated 
with ischemic rest pain (e.g., 40 mm Hg). I f  seden- 
tary, they may not have claudication, and they have 
no rest pain or tissue loss. In this asymptomatic 
no-man's-land, an apparent category 0, they are nev- 
ertheless quite vulnerable and could not heal a foot 
lesion if one was precipitated by minor trauma, re- 
sulting in an immediate drop to category 5. They, 
like patients with clandication in this lower pressure 
strata, have a higher risk of ultimate limb loss than 
those at higher levels. 7-12 
Qualification for the designation "l imb sal- 
vage." The term "limb salwLge" should not be ap- 
plied to patients with critical ischemia, but only to 
therapeutäc outcome and to operations or other inter- 
ventions that are intended to avoid an otherwise 
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inevitable major amputation. Although an unex- 
pected minor amputation after a revasctflarization 
procedure performed on an intact limb constitutes a 
major complication and a treatment failure, a revas- 
cularization procedure in a patient with established 
tissue loss, which allows a minor amputation to heal, 
would qualify as a success, and thus a limb salvage 
procedure. In this regard, minor and major amputa- 
tion needs to be defined. The designation "minor 
amputation" requires retention of a suffidently func- 
tional foot remnant o allow standing and walldng 
without a prosth¢sis. A modified shoe is allowable, but 
a Syme's amputation, because it involves hortening 
and prosthetic fitting, would not qualify as a minor 
amputation and inclusion under the term "limb sal- 
vage." Therefore, minor amputation will be repre- 
sented for the most part by toe or transmetatarsal 
amputations, with Syme's and most high forefoot 
amputations (e.g., Chopart's) being included under 
"major amputations." Revascularization that allows 
healing of a below-lmee amputation when above- 
knee amputation would have been otherwise pre- 
dicted, although in a sense representing partial imb 
salvage, does not qualify under the designation "limb 
salvage" in these reporting standards. Finally, in 
studies that involve the treatment ofischemic ulcers, 
complete and lasting healing should be demon- 
strated for inclusion under the designation of limb 
salvage. Reduction in ulcer area is a permissible nd 
point only in drug trials of short duration. 
Other categorization recommendations. Op- 
erations for microembolism or "blue toe syndrome," 
although offen justified to save the foot fi'om even- 
tual partial or complete loss after ecurrent emboliza- 
tion, do not qualify for inclusion with "limb salvage 
operations," unless there is objective vidence of diffuse 
pedal ischemia, a visible threat of tissue loss (i.e., 
chronic critical ischemia), and a proximal hemody- 
namically significant obstructive l sion is corrected or 
bypassed. Because oftheir uniqueness, uch cases are 
better eported separately. If included in overall re- 
views of experiences with arterial reconstructions, 
those without diffuse pedal ischemia should be listed 
with other hemodynamically insignificant lesions 
(grade or category 0) along with graff structural 
defects or false aneurysms, unless they are associated 
with a significant enough occlusive lesion to cause 
claudication (grade I, categories 1 to 3). The same 
rnles apply to graft or anastomotic stenoses that are 
detected by surveillance programs. Finally, it is rec- 
ommended that the relative portion (%) ofnonheal- 
ing ulcers and gangrene be indicated in reporting on 
those with actual tissue loss (i.e., in category 5). 
OUTCOME CRITERIA 
Outcome after treatment of peripheral arterial 
occlusive disease can be gauged by a number of 
parameters--some reflecting success, others reflect- 
ing failure. In the literatnre, such terms as "technical 
success," anatomic or angiographic success," din- 
ical success," and "hemodynamic success" have been 
used in early assessment, particularly after endovascu- 
lar procedures, whereas patency, limb salvage, and 
continued clinical improvement are terms more com- 
monly applied to late follow-up status. It is desirable 
to reduce these outcome criteria to those that have 
significant value and to apply precise and uniform 
definitions to them. In addition, it is valuable for 
comparative purposes to be able to gange the degree 
ofchange in clinical status in relation to the pretreat- 
ment assessment. This would allow clinical success or 
failure over time to be reported in uniform and ob- 
jective terms. A scheme for this will be presented 
along with guidelines for assessing hemodynamic 
success or failure and patency. 
Criteria for reporting significant change in 
clinical status 
Clinical assessment, when expressed in terms of 
"symptomatic relief," has been notoriously unreli- 
able in the past because it lacked objectivity. Com- 
bining standard clinical categories (as previously de- 
fined) with objective noninvasivc testing (as 
described below) can overcome this weakness. For 
reporting purposes, the designation "clinically im- 
proved" requires an upwärd shiff by at least one 
clinical category (as defined earlier and summarized 
in Table II) except for those with actual tissue loss 
(category 5), who must move up at least wo catego- 
ries and at least reach a level of claudication to be 
considered improved. In addition, to claim cause and 
effect and attribute the improvement to the treat- 
ment, some objective evidence of hemodynamic 
change nee& to be included when revascularization 
procedures (as opposed to exercise or drug therapy) 
are being evaluated or compared, and here a change 
in the ABI of more than 0.10 is recommended. In 
patients in whom the ABI can not be accurately 
measured (e.g., patients with diabetes and rigid cal- 
cified arteries), the toe pressure, which is usually 
unaffected by this, or any measurable pressure distal 
to the revascularization may be substituted. The scale 
shown in Table III details this recommended ap- 
proach for gauging the degree of improvement or 
worsening in individual patients. For group compar- 
isons, the percent ofpatients who have "significantly 
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Table II I .  Recommended scale for gauging changes in clinical status 
+ 3 Markedly improved: No ischemic symptoms, and any foot lesions completely healed; ABI essentially "normalized" (increased to 
more than 0.90) 
+2 Moderately improved: No open foot lesions; still symptomatic but only with exercise and improved by at least one category*; 
ABI not normalized but increased by more than 0.10 
+ 1 Minimally improved: Greater than 0.10 increase in ABII" but no categorical improvement 0rvice versa (i.e., upward categorical 
shift without an increase in AB I of  more than 0.10 )
0 No change: No categorical shift and less than 0.10 change in ABI 
- 1 Mildly worse: No categorical shift but ABI decreased more than 0.10, or downward categorical shiß with ABI decrease l ss than 
0.10 
-2 Moderately worse: One category worse or unexpected minor amputation 
-3  Markedly worse: More than one category worse or unexpected major amputations 
*Categories refer to clinical classification (Table II). 
1"In cases where the ABI cannot be accurately measured, an index based on the toe pressure, or any measurable pressure distal to the site 
of revascularization, may be substituted. 
improved" (i.e., either +2 or +3) can then be com- 
pared. 
COMMENT: Ganging the degree of clinical 
change is the primary goal of this grading scale. The 
use of an ABI change of 0.10 here is not intended as 
indirect evidence of patency but as the least accept- 
able evidence of hernodynamic improvement, o 
guard against the fallibility of basing success on 
symptomatic mprovement alone. It will be noted 
that, in attempting to provide an objective basis for 
claiming "improvement" here, and later for defining 
"hemodynamic success" or "failure" and for sup- 
porting a claim of patency, an ABI change of 0.10 
has been chosen. In an earlier study, Carter 21 recom- 
mended 0.15 as the minimum requirement for sig- 
nificant change. This was widely accepted, and many 
vascular surgeons till prefer this. However, the ad 
hoc committee that originally developed these stan- 
dards believed that a difference of 0.10 was sufficient 
to signify true change, i f  combined with categorical 
clinical improvement, as required. It was thought 
that 0.15 was too strict and might unfairly exclude 
patients who truly benefitted. For example, using a 
0.15 increase as a requirement would categorize as a 
failure a patient with a blood pressure of 120, whose 
ankle pressure increased after treatment from 24 to 
41 mm Hg (from 0.20 to 0.34 ABI), even though 
such a patient would likely be relieved of rest pain. 
Similarly, a patient relieved of claudication by iliac 
percutaneous transluminal angioplasty (PTA) with 
an ABI increased from 0.86 to 1.00 would be con- 
sidered afailure if a 0.15 ABI increase were required. 
Thus the original recommendation has been re- 
tained. 
Hemodynamic success or failure. The term 
"hemodynamic failure" has been used to indicate a 
lack of significant hemodynamic improvement (i.e., 
an increase in ABI) in spite of a patent revasculariza- 
tion. The common setting for this is multilevel dis- 
ease where a proximal reconstruction is performed in 
the face of residual distal disease or "poor runoff." It 
can also be seen after PTA where dissection or elastic 
recoil of an unyielding plaque may result in incom- 
plete restoration of luminal diameter (although this 
can also be considered a form of technical failure). 
Again, for the sake ofuniformity, a specific degree of 
change must be recommended, and for reasons given 
above an increase of less than 0.10 in the distal 
prcssure index constitutes a hemodynamic failure. 
Thus in the specific circumstance of a proximal or 
inflow procedure (e.g., femorofemoral bypass or iliac 
PTA) being performed in the face of outflow disease 
or poor runoff (e.g., superficial femoral artery occlu- 
sion), failure to increase the ABI by at least 0.10 is 
considered a hemodynamic J~ilure. Conversely, in- 
creasing the ABI by more than 0.10 can be consid- 
ered a "hemodynamic success," but it would not be 
considered a "clinical success" without categorical 
clinical improvement, asdescribed earlier. 
Criteria for patency. Articles in scientific jour- 
hals should only accept patency rates that are based 
on objective findings. A bypass graft or otherwise 
reconstructed arterial segment may be considered 
patent when one of the following five criteria is mer. 
Beyond the last date of such proof of patency, they 
must be considered lost to follow-up. 
1. Demonstrably patent graft by an accepted vascu- 
lar imaging technique, such as arteriography, Du- 
plex ultrasound color-flow scan, or magnetic res- 
onance imaging. 
2. The presence ofa palpable pulse, or the recording 
of a biphasic or triphasic Doppler wave form at 
tw0 points directly over a superficially placed graft. 
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3. Maintenance of the achieved impr0vement in the 
appropriate segmental limb pressure index, that 
is, not more than 0.10 below the highest postop- 
erative index. Although a greater eduction in 
pressure index may occur and the graft or re- 
opened segment may still be patent, imaging 
proof is required in these instances or any other 
doubtful or marginal circumstances covered under 
criteria 2, 3, or 4. To avoid the confusing effects of 
distal runoff disease, the most appropriate pres- 
sure index for this purpose is at the hext level 
beyond the revascularized segment or distal anas- 
tomosis (see comment below). 
4. Maintenance of a plethysmographic tracing distal 
to the reconstruction that is at least 50% or 5 mm 
greater in magnitude than the preoperative value 
and close to the postoperative alue. (This is the 
weakest criterion and acceptable only when accu- 
rate pressures cannot be measured, as with calcific 
arteritis in a diabetic patient. However, even in 
such cases, stronger evidence of patency, in the 
form of imaging, is clearly preferred.) 
5. Direct observation of patency at operation or 
postmortem examination. 
COMMENT: Although palpable pedal pulses 
that are readily felt by an experienced observer are 
adequate for routine clinical assessment, such obser-' 
vations (and particularly comments to this effect in 
the patient's record by nurses, residents, or fellows) 
cannot be accepted as proofofpatency for reports in 
scientific journals. Accurate patency data are so cru- 
cial to comparisons of arterial reconstructive teeh- 
niques that reliable objective methods taust be used. 
Duplex or color-flow Doppler scanning is now an 
accepted and commonly used method of graft sur- 
veillance and should be available in most centers. 
Failing this, Doppler measurement of ankle and bra- 
chial pressures can be used. At the time of the origi- 
nal Standards, before color-flow duplex scanning was 
widely available, the use of Doppler-derived pressure 
measurements was a reasonable xpediency because 
angiographic follow-up was impractical. It allowed 
investigators to claim patency in the absence of other 
documentation, using retrospective vascular labora- 
tory data. Now, the debate over the significance of a 
0.10 versus 0.15 change in ABI has been tempered 
by the duplex scan, which can and should be used to 
settle the issue ofpatency in equivocal cases. 
At this point, it is worth reemphasizing that the 
designation of "clinically improved" is based on cate- 
gorical clinical improvement plus objective vidence 
of hemodynamic improvement (i.e., the ABI). He- 
modynamic success, or conversely hemodynamic fail- 
ure, also applies to the entire limb and therefore also 
uses a distal monitoring site (i.e., the ABI). In con- 
trast, patency applies to the revascularized or by- 
passed segment only, and ifimaging studies or direct 
observation are not available, one should use the 
pressure index from the hext level beyond that segment 
(e.g., the thigh-brachial index rather than the ABI 
for a proximal bypass graft or PTA). This is recom- 
mended to avoid the confusing effects of new or 
progressing occlusive disease between the revascular- 
ized segment and the point ofpressure monitoring. 
Failed and failing grafts. A graft hat has lost its 
patency--that is, has thrombosed--is considered a
"failed" graft. This is in contrast to a "failing" graft, a 
graft that is still demonstrably patent but that has 
developed orte or more stenoses that, if unrelieved, 
may lead to thrombosis. Such lesions may or may not 
produce symptoms or a significant drop in the resting 
ABI but can be detected by duplex surveillance of the 
graft and its anastomoses. Furthermore, their correc- 
tion significantly improves assisted primary and sec- 
ondary patency rates, 22 as defined below. Diagnostic 
criteria include a peak systolic velocity in the stenosis 
that is greater than a certain level (e.g., 150 cm/sec) 
or is significantly greater than (e.g., at least 2.5 
times) that of an adjacent "normal" segment. 23With 
greater degrees ofstenosis, the end diastolic velocity 
in the stenosis usually becomes imilarly elevated and 
the ratio of accelerated to background velocity 
climbs. 24 Failure has also been predicted by an overall 
reduction in graft flow velocity below 45 cmflsec, 24 
but this criterion applies mainly to femoropopliteal 
vein grafts, not tibial bypass grafts or those that using 
a prosthetic bypass graft. The specific riteria used are 
not yet standardäzed and differ somewhat from cen- 
ter to center. Their accuracy in predicting the actual 
degree of stenosis (e.g. , )50% versus >75%) is also 
not well established, nor is the degree of stenosis 
beyond which failure is inevitable. Therefore, confir- 
matory arteriography is usually deemed necessary 
before intervening. Nevertheless, the concept and 
definition of a failing graft has gained wide accep- 
tance and deserves inclusion in these reporting stan- 
dards. Until standard iagnostic riteria re accepted, 
reports on this aspect should include the duplex 
criteria used, angiographic confirmation, or both. 
Patency status: primary vs secondary patency. 
With the help of graft thrombectomy or thromboly- 
sis, revision or "redo," it mäy be claimed that the 
original graft is still patent. It is important in this 
regard to separate "primary" from "secondary" pa- 
tency. A graft is considered to have "primäry" pa- 
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tency if it has had uninterrupted patency with either 
no procedure performed on it or a procedure (e.g., 
transluminal dilation or a proximal or distal exten- 
sion to the graft) to deal with disease progression in 
the adjacent native vessel. Thus the only exceptions 
that do not disqualify the graft for primary patency 
are procedures performed for disease beyond the graft 
and its two anastomoses. Dilations or minor revisions 
performed for stenoses, dilations, or other structural 
defects, or closing missed arteriovenous fi tulas in an 
in situ vein bypass graft before occlusion do not con- 
stitute exceptions, as they are intended to prevent 
eventual graft failure. 
When originally proposed, 1 considerable objec- 
tions were raised against his last rule goveming pri- 
mary patency, 25 understandably, because bypass 
grafts that never occluded but underwent minor pro- 
cedures to protect patency were considered the same 
as those that had actually thrombosed, that is, they 
were all listed as secondary patency data. Ultimately, 
the additional designation of "assisted primary pa- 
tency" was suggested to apply to this situation, in 
which patency was never lost hut maintained by pro- 
phylactic intervention. 26This has proven useful and 
is included in this revised version. 
If  graft patency is restored after occlusion by 
thrombectomy, thrombolysis, or transluminal ngio- 
plasty, and/or  any problems with the graft itself or 
one ofits anastomoses require revision or reconstruc- 
tion, all must be listed under "secondary" patency. A
"redo" or secondary reconstruction, as defined later, 
does not contribute to secondary patency unless most 
of the original graft and at least one anastomosis are 
retained in continuity. 
It should be understood that both primary and 
secondary patency rates are important. The former is 
important in judging the natural history of a graft or 
reconstructive procedure, and the latter is important 
to indicate how long function can be preserved with 
the aid of dose surveillance and the use of secondary 
or adjunctive procedures. Both provide valuable in- 
formation, hut when only one or the other patency 
rate is presented and one is not identified, compari- 
son between different reports on the same type of 
reconstructive procedure is ditficult, if not impossi- 
ble. Therefore, it is recommended that in each re- 
port, both primary and secondary patency rates be 
presented, and the pätency rate untier discussion is 
identified as primary or secondary. The same applies 
to the assisted primary patency rate, should it be 
used. Thus it is appropriate, in analyzing an experi- 
ence with extremity bypass or in comparing two such 
procedures where a program of graft surveillance and 
intervention for preservation of patency is used, to 
present all three patency rates to demonstrate the 
intrinsic durability of the primary procedure, the 
impact of graft surveillance and prophylactic inter- 
vention, and the ability to restore function to a failed 
graft. 
It has been suggested that secondary reconstruc- 
tions that do not qualify under the definition of 
secondary patency be allowed to contribute to "ter- 
tiary patency," that is, patency across the same 
limb segment achieved by one or more additional 
procedures that do not preserve, in continuity, 
most of  the original graft and one anastomosis. 
Although this adds some perspective regarding the 
ultimate status of  the limb, and such procedures 
do contribute to limb salvage and function, this is 
not a recommended reporting standard. It only 
gauges the overall success of  surgical management 
and not the merits of the original bypass or revas- 
cularization procedure, which is the primary focus 
of  patcncy analysis. 
Estimating patency rates. Mthough subject o 
some artäfact, so that projected and actual patency 
rates are not necessarily the same, the life table (LT) 
method is one of the best and most commonly used 
ways of presenting patency data on patients who 
undergo a revascularization procedure at different 
points in time and are followed-up for different 
lengths of time. Only the LT method was recom- 
mended for this purpose in our original standards. ~ It 
is still an accepted method ifits rules are followed, 
but its limitations must be appreciated. The Kaplan- 
Meier survival estimate is an equally acceptable 
method under most circumstances. Both of these 
methods are described and compared in the follow- 
ing paragraphs. 
The LT method was best characterized byPeto et 
al.27,28 in 1976 and 1977 in two articles in the British 
Journal of Cancer, but such methods were earlier 
described by Berkson and Gage in 195029 and also 
by Cutler and Ederer in 1958. 3o It was originally 
applied to the follow-up data of  patients with differ- 
ent forms of  cancer and cancer therapy. The LT 
method has two features that characterize the tech- 
nique. The first is that events on the survival curve-- 
for example, graft failures--are grouped into inter- 
vals. Survival rates are then calculated for each of 
these intervals and are used to generate cumulative 
patency rates that describe the survival curve. The 
second important feature is the assumption that any 
individuals lost t O follow-up during an interval (also 
called censored ata) are treated as withdrawn at the 
midpoint of the interval. It is this assumption that 
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Table IV. Life table example 
A 
Interval (mo) 
B C D E 
No. at risk at No. failed Withdrawn Interval 
beginning of during during failure 
interval interval interval rate 
F G 
Cumulative Standard 
patency rate error 
0 to ó 64 3 2 0.048 95.2% 2.60% 
6 to 12 59 10 0 0.169 79.1% 4.71% 
12 to 18 49 5 0 0.102 71.0% 5.46% 
18 to 24 44 4 0 0.091 64.6% 5.79% 
24 to 30 40 2 1 0.051 61.3% 6.03% 
30 to 36 37 3 5 0.087 56.0% 6.11% 
36 to 42 29 1 2 0.036 54.0% 6.80% 
42 to 48 26 0 4 0.000 54.0% 7.18% 
48 to 54 22 0 4 0.000 54.0% 7.81% 
54 to 60 18 1 1 0.057 50.9% 8.41% 
60 to 66 16 0 3 0.000 50.9% 8.92% 
6ö to 72 13 0 10 0.000 50.9% 9.89% 
72 to 76 3 0 3 0.000 50.9% 20.59% 
Column E = C / (B - 1/2D). 
Column F = (1 - column E) x previous interval's cumulative patency rate. 
Column G = F × %/(1 - [F / 100]) / C. 
leads to the characteristic correction to the calculated 
failure rate for a given interval: 
Failure rate =" 
Number of failures 
Number at risk - 1/2 Number ofwithdrawals 
This correction considers the individuals who 
were withdrawn to contribute to the risk pool for 
only half of the interval. However, this correction is 
mathematically equivalent to increasing the interval 
failure rate by the number ofexpected failures in half 
of the withdrawal group: 
Number of failures 
Failure rate = 
Number at risk 
+ Failure rate x 1/2 Number of Withdrawals 
The further consequence of this correction for 
censored ata or withdrawals i that the failure rate is 
assumed to be uniform over the interval. With this in 
mind, the use of the stair-step graphical presentation 
of the LT plot is not strictly necessary because the 
cumulafive patency rate is the resulting condifional 
probability at the end of the interval based on the 
failure rate over the entire interval. The LT graph can 
thus be represented by straight line connections be- 
tween the patency estimates located at the end of 
each interval. In this presentation, the only intervals 
with level lines are those with no failures. 
LT analysis hould include the following columns 
in the table (alphabetically listed as in the example 
presented in Table IV): (A) intervals in months; (B) 
number of grafts at risk at the start of the interval; 
(C) number failed during the interval; (D) number of 
pafients withdrawn with patent grafts during the 
interval, due to death, loss to follow-up, or with 
follow-up that ends during that fime interval (these 
three may be tabulated in separate columns, then 
combined); (E) interval failure rate; (F) cumulafive 
patency rate; and (G) standard error. Cumulafive 
mortality data, though not a requisite part of the LT, 
add perspecfive and may be included in an addiuonal 
column for that reason. 
The following paragraph summarizes, as simply 
as possible, the determinafion and serial calculafion 
of each of the columns in the LT. Calculauons may 
be followed by referring again to the example pre- 
sented in Table IV. (A) Interval in months can be 
chosen to represent any desired time span shorter 
than the review period, and they need not be equal. 
It is useful to have the first interval as 0 to i month to 
show early patency, and 3- to 6-month intervals are 
commonly chosen thereafter. More frequent inter- 
vals increase precision. (B) Number of grafts at risk at 
start in the first interval are the number entered into 
the study, and in subsequent intervals are derived by 
subtracting columns C and D from B in the previous 
interval. (C) Number ofgraftsfailed are those that 
had known occlusion occurring during this interval. 
(D) Number of grafts withdrawn: patients with 
patent grafts in the previous interval who died or 
were lost to follow-up during the interval or did not 
complete the present interval. (E) Interval patency is
calculated as I - interval failure rate, which is in turn 
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Fig. 1. Patency curve by life table method (data in Table IV). 
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calculated by dividing column C by (column B minus 
half of  column D), according to the theoretical con- 
siderations given above. (F) The cumulative patency 
rate is 100% for the first interval, and for each succes- 
sive interval is obtained by multiplying the present 
interval patency rate by the cumulatäve patency rate 
in the previons period. (G) Standard errors in per- 
cent are calculated as 100 x F x square root of (1 
- F) /B,  where F equals the cumulative patency rate 
and B the number at risk at the start of the interval. 
An equally appropriate alternative method for 
estimating patency is the Kaplan-Meier survival esti- 
mate (KM), 31 which is also called the product-limit 
method. The KM estimate is different from the LT 
method in that data are not grouped into intervals. 
Events on the survival curve occur only at individual 
failure points. No assumptions are made about the 
failure rate of withdrawals. In contrast o the LT 
method, graphical presentation of the ICM survival 
curve should use the stair-step method because, be- 
tween events on the KM curve, nothing is known or 
assumed about the failure rate. One can conceptual- 
ize the KM method as an LT method with small 
intervals containing asingle event. The same data are 
presented in Table IV and Fig. 1 for LT analysis and 
Table V and Fig. 2 for analysis by the KM method. 
The final endpoints are almost identäcal. 
The LT mcthod makes calculations easier for very 
largc amounts of data, and this may be the main 
justification for using it rather than the KM. How- 
ever, vascular patency studies do not usually have 
prohibitively large data sets, and such considerations 
have become almost moot with the advent of  desk- 
top computers. Indeed, the LT method is not strictly 
valid for numbers less than 30, whereas the KM 
method remains appropriate for any data size. 32 Ei- 
ther method is acceptable ifproperly used and docu- 
mented. The data shown in Figs. 1 and 2 were 
comparatively tested by adding a number of  early 
patent cases ("front loading') and by subtracting an 
equal number of  early withdrawals, and in each in- 
stance the late patency rates were still roughly equiv- 
alent. 
Complete LT or KM data should be submitted as 
a table with each report, to allow the validity of the 
data to be checked, even though it may be the choke 
of the editor only to publish the graph. Numbers for 
the paUeuts at risk at the start of each interval (peri- 
odically for the KM) or the standard error for each 
estimate of patency taust be displayed using bars. 
When comparing multiple curves or plots in a single 
figure, these bars may clutter the graph or figure. 
Pointing the bars in opposite directions or using bars 
at selected rather than all intervals will usually obviate 
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Table V. Kaplan-Meier example 
A B C D E 
No. at risk at Failure 
Event time (mo) event No. of events Withdrawn rate 
F G 
Cumulative Standard 
patency rate error 
2.5 64 1 0 0.016 98.4% 1.54% 
3.2 63 0 1 0.000 98.4% 1.55% 
4.1 62 1 0 0.016 96.8% 2.18% 
4.4 61 0 1 0.000 96.8% 2.20% 
4.6 60 1 0 0.017 95.2% 2.68% 
6.2 59 1 0 0.017 93.6% 3.08% 
6.4 58 1 0 0.017 92.0% 3.42% 
70.9 4 0 1 0.000 50.7% 17.79% 
71.5 3 0 1 0.000 50.7% 20.55% 
75.3 2 0 1 0.000 50.7% 25.17% 
75.7 1 0 1 0.000 50.7% 35.59% 
*The mid-portion of  the table has been omitted for brevity. 
Column E = C / B 
Column F = (1 - column E) × previous interval's eumulative patency rate. 
Column G = F × ~/(1 - [F / 100]) / C 
this clutter. When the standard error of the patency 
rate estimate xceeds 10%, the curve either should 
not be drawn or should be represented by a dotted 
line as a means of indicating lack of reliability of the 
estimate. Comparisons of patency curves should be 
performed using the log-rank test of significance. 33
Whenever possible, separate LTs should be pro- 
vided for each type of operative procedure. Gener- 
ally, one should not mix data from several different 
levels of infrainguinal bypass grafts but report sepa- 
rately above-knee femoropopliteal bypass grafts, be- 
low-knee femoropopliteal bypass grafts, and femoral 
infrapopliteal bypass grafts, for cxample. Whcrc per- 
tinent, specifically where differences are claimed, addi- 
tional LT or KM plots should be reported for differ- 
ent indicauons for operation (e.g., claudication vs 
foot salvage), for different runoff status, or for any 
major risk or treatment factors that appear to affect 
patency (e.g., with and without antiplatelet therapy, 
or diabetic vs nondiabetic), particularly if they are 
claimed to do so. In some instances, interdepen- 
dence of variables will limit the confidence with 
which conctusions may be drawn from this sub- 
grouping of data. In this situation, it is orten appro- 
priate to apply multivariate analysis using the Cox 
hazard regression analysis. 34 
COMMENT: It is not uncommon for authors 
who report on revascularization procedures to ac- 
knowledge an inifial failure rate but then exclude 
such failures from the calculation of cumulative pa~ 
tency rates. Although information is not withheld, 
the practice is deceiving. For example, if 25% of a 
particular intervention initially failed but 80% of 
those successful were still patent after a given time 
period, only 60% of those initially treated will have 
benefitted. Similarly, with such an initial failure rate, 
iftwo thirds ofsuccessful grafts remained patent, less 
than half would have benefitted. This "intent to 
treat" rule may occasionally seem too strict, as in a 
patient in whom a bypass procedure is canceled be- 
cause of a myocardial infarction suffered uring in- 
duction of anesthesia, or when there is inability to 
gain percutaneous access for introduction of a caval 
filter. However, to arbitrarily allow such "reason- 
able" variances would create more problems than it 
would solve, and therefore the "intent o treat" rule 
has been retained. 
IDENTIFY ING AND GKADING FACTORS 
THAT MODIFY OUTCOME 
Clinical reports that evaluate revascularization 
procedures, particularly those that compare different 
treatment methods, may be difficult to interpret 
when differences in factors that can affect outcome 
are not identified and characterized. For example, for 
infräinguinal bypass procedures, diabetes, tobacco 
usage, and occlusive disease distäl to the rcvascular- 
ization ("runoff") mäy affect patency rates and the 
degree ofimprovement, whereas cardiac, pulmonary, 
and renal status may influence operative mortality 
rates and long-term survival rates. Grading such fae- 
tors in severity, with uniform definitions for (1) mild, 
(2) moderate, and (3) severe, would allow severity 
indiees to be ealeulated for intergroup comparison. 3~ 
The following simplified grading system is offered for 
common risk factors, reeognizing that other altema- 
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Fig. 2. Kaplan-Meier patency curve (data in Table V). 
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tive schemes may have been proposed but none has 
gained universal acceptance. A scheme for grading 
"runotF' is also proposed. 
Diabetes: 0 =none;  1 = adult onset, controlled 
by diet or oral agents; 2 = adult onset, insulin- 
controlled; 3 = juvenile onset. 
Tobacco use: 0 = none or none for last 10 years; 
1 = none current, but smoked in last 10 years; 2 = 
current (includes absunence less than 1 year), less 
than 1 pack/day; 3 = current, greater than 1 pack/  
day. 
Hypertension: 0 =none (cutoff point, diastolic 
pressure usually lower than 90 mm Hg); 1 = con- 
trolled (cutoffpoint, diastolic pressure usually lower 
than 90 mm Hg) with single drug; 2 = controlled 
with two drugs; 3 = requires more than two drugs or 
is uncontrolled. 
Hyperlipemia: 0 = cholesterol (low-density li- 
p0protein and total) and triglyceride levels within 
normal limits for age; 1 = mild elevation, readily 
controllable by diet; 2 = moderate levation requir- 
ing strict dietary control; 3 = same as 2, but severe 
enough to require dietary and drug control. 
Cardiac status: 0 = asymptomatic, with normal 
electrocardiogram; 1 = asymptomatic but with either 
remote myocardial infarction by history (>6 
months), occult myocardial infarcUon by electrocar- 
diogram, orfixed defect on dipyridamole thallium or 
similar scan; 2 = any one of the following: stable 
angina, no angina but significant reversible perfusion 
defect on dipyridamole thallium scan, significant si- 
lent ischemia (->1% of time) on Holter monitoring, 
ejecnon fracuon 25% to 45%, controtled ectopy or 
asymptomauc arrhythmia, history ofcongesuve heart 
failure that is now well compensated; 3 = any one of 
the following: unstable angina, symptomatic or 
poorly controlled ectopy/arrhythmia (chronic/re- 
current), poorly compensated or recurrent conges- 
uve heart failure, ejecfion fracUon less than 25%, 
myocardial infarction within 6 months. 
Carotid discase: 0 = no symptoms, no evidence of 
disease; 1 = asymptomatic hut with evidence of dis- 
ease determined by duplex scan or other accepted 
noninvasive test or arteriogram; 2 = transient or 
temporary stroke; 3 = completed stroke with perma- 
nent neurologic deficit or acute stroke. 
Renal status: (refers to stable levels, not transient 
drops or elevations in response to intravenous medi- 
cation, hydraUon, or contrast media) 0 = no known 
renal disease, normal serum creatinine level; 1 = 
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moderately elevated creatinine level, as high as 2.4 
mg/dl;  2 = creatinine level, 2.5 to 5.9 mg/dl ;  3 = 
creatinine l vel greater than 6.0 mg/dl ,  or on dialysis 
or with lddney transplant. 
Pulmonary status: 0 = asymptomatic, normal 
chest x-ray film, pulmonary function tests within 20% 
of predicted; 1 = asymptomatic or mild dyspnea on 
exertion, mild chronic parenchymal x-ray changes, 
pulmonary function tests 65% to 80% of predicted; 
2 = between 1 and 3; 3 = vital capacity less than 
1.85 L, FEV~ less than 1.2 L or less than 35% of 
predicted, maximal voluntary ventilation less than 
50% of predicted, Pco 2 greater than 45 mm Hg, 
supplemental oxygen use medically necessary, or pul- 
monary hypertension. 
COMMENT: Goldman's cardlac risk index is not 
recommended, even though it combines nine inde- 
pendent factors that correlate with life-threatening 
and fatal complications, 36 because it has been shown 
not to correlate with cardiac events in vascular sur- 
gery patients, presumably because their more seden- 
tary lifestyle masks some of the evidence of cardiac 
disease. 37 Cardiac screening tests, or even the results 
of coronary angiography, offer acceptable alternative 
information for stratifying patients' cardiac risk, but 
their routine application to all vascular surgery pa- 
tients can not be justified at this time. Eagle et alY ,39 
has identified five risk factors for coronary disease 
(age more than 70 years, diabetes, history or electro- 
cardiographic evidence of myocardlal infarction, an- 
gina, and congestive heart failure) that, when used 
in combination, allow the selective application ofcar- 
dlac screening tests and, in turn, lead to stratification 
ofrisk ofperioperative cardiac ischemic events. Such 
an approach has proven acceptable for reports on 
aortic aneurysm surgery but is, as yet, unproven in 
patients with limb ischemia. 38,39 In the absence of a 
proven scheme for stratifying the cardiac risk of pa- 
tients who undergo vascular surgery, the original 
cardiac risk score has been modified to include both 
clinical information and the results of cardiac screen- 
ing tests. 
It is understood that it will not be appropriate, or 
feasible, to include all of the above risk factors in 
each report. Nevertheless, reports that claim im- 
proved patency rates, decreased early or late mortal- 
ity rates, or fewer pulmonary complications, for ex- 
ample, should support their claim by including 
standardized information on appropriate risk factors. 
It should be apparent hat risk factors that affect 
mortality rates are not identical with those that relate 
to patency. For example, cardiac status dominates 
mortality risk, with pulmonary and renal status also 
contributing to a degree. For patency and limb sal- 
vage rates, or other measures oflong-term success of 
revascularization procedures, moldng, diabetes, and 
renal status, as well as severity of runoff disease (see 
below) commonly correhte with outcome, as does 
hyperlipidemia to a lesser degree. 
Runoff. It is understood that no scheme for 
grading runoff is perfect, is likely to be universally 
accepted, or will always correlate with early or late 
graft failure. Nevertheless, a grading scheme that 
provides areasonable degree ofcorrelation with out- 
come is desirable. Simpler (good/poor or 1 to 4) 
grading schemes have been used in the past, mainly 
for ganging the outcome of femoropopliteal bypass 
grafting. The one proposed here holds the advantage 
that it may be applied to any level of distal anastomo- 
sis rather than just to femoropopliteal bypass grafts. 
Since its introduction, this scheme has been tested by 
correlation against patency in numerous reports, 
with mixed results. In general, it has not correlated as 
well with the patency of infrainguinal vein grafts 
(where patency rates are usually good despite com- 
promise runoff) as it has with infrainguinal bypass 
procedures performed with grafts other than greater 
saphenous vein. The previous version 1did not sutfi- 
ciently accommodate pedal artery/arch patency, 
which, now that excellent runoff visualization is be- 
ing regularly obtained and pedal bypässes are com- 
mon, is clearly needed. Finally, problems have arisen 
when infrainguinal bypass grafts with different levels 
of distal anastomosis have been mixed together or 
compared. For example, a bypass graft to a popliteal 
artery with single tibial artery runoff (runoff score, 7) 
is not comparable to a bypass graft to a patent ibial 
artery (runoff score, 1), even though the outflow to 
the foot is identical. Therefore, it should be under- 
stood that this runoff scheme is useful for comparing 
bypass grafts grouped according to the level of distal 
anastomosis, for example, femoral or popliteal or cru- 
ral artery, but not if these levels are mixed. Some 
modifications have been proposed (e.g., adding 
weighting coetficients), but these have not been val- 
idated prospectively as being better than the original 
scheme and complicate the scheine even more. For 
these reasons and its relatively greater complexity it is 
not yet widely used, but because no other better 
system has come along in the last decade and re- 
placed it, it has been retained in these standards, with 
modification to accommodate differences in pedal 
artery patency and clarification for easier understand- 
ing and application. However, it is realized that its 
utility is limited by the quality and accuracy of data 
collected from arteriograms and the types ofcompar- 
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Table VI, A. Weighting of runoff arteries (total of three units)--site 
Number of units assigned 
Site of distal 
anastomosis (artery) 3 2 
Common iliac 
External i iac 
Common femoral 
Popliteal above-knee 
Popliteal below-knee 
Anterior tibial 
Posterior tibial 
Peroneal 
Pedal/inframalleolar 
Common femoral 
Distal popliteal 
External i iac 
SFA 
SFA 
Distal tibial 
Distal tibial 
Pedal runoff 
Hypogastric 
Profunda femoris 
Profunda femoris 
Anterior fibial 
Posterior tibial 
Peroneal 
Pedal arch 
Pedal arch 
Collaterals to anterior and posterior 
tibial arteries 
SFA, Superficial femoral artery. 
Table VI, B. Weighting ofrunoffarteries (total ofthree units)--occlusion 
Number of points assigned per unit 
Degree of occlusion 3 2.5 2 1 0 
Major runoffvessels Occluded Occluded less than ½ 50% to 99% greatest 20% to 49% greatest Less than 20% greatest 
throughout of length; visible stenosis stenosis stenosis 
length collaterals 
Pedal runoff No primary Partially patent or In line continuity One or more Fully patent pedal 
pedal artery fully patent beyond with patent subcritical runoff (<20% 
patent critical in line outflow vessel but stenoses distally stenosis) 
occlusive lesion incomplete arch but no in line 
isons that it helps define (e.g., similar bypass grafts to 
similar outflow sites). Therefore, it is not recom- 
mended to the exclusion of other schemes. 
As seen in Table VI, this scheme grades both the 
degree of occlusion and the relative contribuuon to 
outflow ofeach runoffvessel, from 0 to 3, then adds 
1 to the product of these two grades, resulung in a 
decimal scoring system that assigns 1 to a widely 
patent runoff and 10 to an isolated, blind segment 
with no major vessel runoff. In this scheine, higher 
values correspond with higher resistances o that 
resistances in series and in parallel (as in axillobifemo- 
ral and sequenual bypasses) can be graded. Calcula- 
tions for some of the more complex examples ofthis 
scheme are illustrated in Figs. 3 and 4. Obviously, 
most calculauons will be much simpler than these. 
EXPLANATION: 
1. Three "weighung units" are divided among 
the major runoff arteries in the segment below or 
beyond the terminal anastomosis, according to their 
normal relative contribufion to runoff or outflow. 
The dominant oftwo runoffvessels is assigned two of 
the three units (e.g., superficial femoral = 2, pro- 
funda femoris = 1), whereas three more or less equal 
runoffvessels, ike the three infrapopliteal rteries, are 
assigned one unit each (see Table VI and Fig. 3, A). 
A normally single vessel outflow (e.g., the popliteal 
artery in an above-knee f moropopliteal bypass graft) 
may receive all three weight units, or these units may 
be individually assigned to each of its runoff vessels 
(e.g., the tibial and peroneal arteries) depending on 
which is considered to present he greatest degree of 
occlusive disease and resistance to runoff (i.e., the 
highest calculated runoffscore). Weighting units for 
each lower extremity artery are shown at the top of 
Table VI. 
2. A "resistance value" is also assigned to each 
outflow artery, with a maximum resistance value of 3. 
As shown in the bottom half of Table IV, three 
"resistance" units are assigned to a vessel that is 
totally occluded throughout i s length, two units to 
one with a 50% to 99% stenosis, one unit for a 20% to 
49% stenosis, and none ifwidely patent. 
3. A modified scheme is offered for pedal artery 
runoff. In pedal or paramalleolar bypass grafts or 
those to a single patent infrageniculate artery termi- 
naUng in the pedal arch, the recipient artery or the 
pedal arch may be assigned all three weighUng units, 
whichever offers the highest resistance. In grading 
the resistance of the pedal arch, zero is assigned for 
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Fig. 3. A, Bolder numbers indicate value, out of possible 
total of 3, assigned to each vessel; numbers in finer print 
indicate values assigned to varying degrees of occlusion 
(Table l-V). B, Runoff resistance values are calculated as 
follows for grafts that enter the three levels indicated: Level 
A, superficial femoral = 2 x 3; profunda femoris = 1 x 0; 
total = 6 + 0 + 1 = 7. Level B, distal popliteal blind 
segment = 3 X 3 + 1 = 10. Level C, anterior Ubial = 2 x 
0 ;arch= 1 x0 ; to ta l=0+0+ 1 = 1. 
completely patent arch connecting with retrograde 
flow back into the other pedal artery (e.g., lateral 
plantar or medial tarsal), 1 for patent arch with no 
retrograde outflow, 2 for a diseased or partially oc- 
cluded arch, and 3 for little or no arch visualized. 
4. The sum of  the products of  the weighfing unit 
multiplied by the resistance value for each major 
runoffartery is added to a base "resistance" o fone,  in 
recognit ion of  the fact that even a widely patent 
distal bed offers some resistance. This creates a deci- 
mal runoffresistance score, in which a blind segment 
carries a value of  10 and a widely patent system is 
scored as 1. The contribution ofeach occlusive lesion 
to runoff resistance depends on its artery's relative 
weight. Thus a 60% stenosis of  a posterior tibial 
artery below a below-knee femoropopliteal bypass 
7 
Fig. 4. In each of three graft configurations (A to C), 
individual runoffvalues for right and left limbs are 7 and 4, 
respectively. Values for aortobifemoral stem (A), entire 
right axillofemoral graft (B), and proximal axillofemoral 
stem (C) are all 2.5 (1 /R  = 1/4 + 1/7 = 11/28 = 
1/2.5). However, distal axillofemoral limb (C) has runoff 
resistance value of 7. D shows a sequential bypass graft 
where resistance values ofproximal and distal limbs are 10 
and 1, respectively. Combined they give a resistance value 
for proximal stem of 0.9 (1 /R  = 10/10 + 1/10 = 
11/10 = 1/0.9). 
graft would have a resistance value of  (2 × 1) 2 
points, the same stenosis in the superficial femoral 
artery below a femorofemoral  bypass graft would be 
assigned (2 x 2) 4 points, whereas this degree of  
narrowing in the popliteal artery below a femoropop-  
liteal above-knee bypass graft would contribute (2 x 
3) 6 points to the runoffscore. 
5. In muluple outf low bypass grafts, as in the two 
limbs of  aortobifemoral and axillobifemoral bypass 
grafts, the reciprocal sum of  each outf low artery is 
added in grading resistance in the proximal limb or 
stem (i.e., 1 /R  stern = 1 /R  left l imb + 1 /R  right 
l imb), but each distal l imb of  the graft is graded alone 
for correlation with graft l imb patency (see examples 
given in Fig. 4). 
I f  a simplified four-level runoff grade is desired, 
the above system can be used in part to produce a 0 
to 3 score. I f  two or more major vessels constitute 
the normal runoff, the "weighting units" above (see 
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explanation #1) can be applied in an all-or-none 
fashion, assigning those points when there is a hemo- 
dynamically significant occlusive lesion (e.g., >50% 
stenosis) in the vessel in question. For example, for 
bypass grafts that terminate in the common femoral 
artery, 2 out of a total of 3 points would be assigned 
if the superficial femoral artery was occluded. Be- 
cause bypass grafts to the popliteal artery are usually 
affected by crural artery occlusive disease, this same 
approach can be used. Thus an occluded posterior 
tibial artery and a 60% stenosis of the anterior tibial 
origin would receive 2 out of 3 points, much like 
previous 1 to 4 grading schemes. Bypassing to a 
single tibial artery or the dorsalis pedis are examples 
of a normally single-vessel runoff. Because it is un- 
likely that this procedure would be performed to a 
vessel with a hemodynamically significant stenosis, 
runoff will normally be determined by the pedal 
arch, and the 0 to 3 score offered for this above 
(see exp!anation #3) can be applied. Arbitrarily, 1 
point would be added to this score in bypass grafts 
to a per0neal artery, in recognition of its lack of 
direct connection with the pedal artery circulation. 
These simpler alternatives are offered as a compro- 
mise, for use when runoff grading is included in 
the analysis along with other risk factors mainly 
to characterize overall case severity in reported 
series. The full scheme is still recommended when- 
ever runoff is a critical aspect of the outcome 
comparison. 
CATEGORIZAT ION OF OPERATIONS AND 
PROCEDURES 
Definitions. It is important o identify, if not 
separate, primary and secondary operative proce- 
dures, principal and adjunctive procedures, and types 
of procedures that differ characteristically in what 
they basically accomplish (e.g., reconstructive, re- 
storative, nonreconstructive, and ablative). The fol- 
lowing definitions are suggested and should be fol- 
lowed for uniform reporting. A "primary" operation 
or procedure is the first of a given type ever per- 
formed on a particular arterial segment. Subsequent 
operations, or other revascularization procedures of 
the same type, performed on the same arterial seg- 
ment are designated "secondary." For example, if 
profundaplasty or balloon angioplasty of the superfi- 
cial femoral artery fails to adequately relieve foot 
ischemia, and a femoropopliteal or femorotibial by- 
pass procedure issubsequently performed, these later 
procedures may still be considered primary proce- 
dures because they are entirely different ypes of 
operations. However, if a femoropopliteal bypass 
procedurc has been performed and it is redone or 
extended own to a tibial artery, these two later 
procedures would be called secondary operations. 
Slach secondary procedures, evcn ifperformed as the 
first operation in a different institution or by a differ- 
ent surgeon in the same insti1~tion, are still consid- 
ered secondary operations. 
A "principal procedure" is the one that the sur- 
geon believes to contribute the most to improving 
the arterial circulation. An "adjunctive procedure" is
any other simultaneous or planned subsequent (i.e., 
stagcd) procedure that is designed to augment the 
effects of the principal procedurc, such as arterial 
balloon dilation, sympathectomy, or profundaplasty 
performed with a femoropopliLteal bypass procedure. 
An "ancillary procedure" is one that does not con- 
tribute to the overall hemodynamic ettèct, such as an 
intraoperative arteriogram, a sartorius muscle flap for 
coverage, or a "prophylactic" fasciotomy. 
An "elective operation" is one that is performed 
without urgency and is scheduled uring regular 
operating time at the mutual convenience of both 
the patient and the surgeon. An "urgent operation" 
is one that is intended to be performed as soon as the 
necessary preoperative preparation and diagnostic 
studies can be completed. An "emergency opera- 
tion" is one that taust be performed as soon as 
possible, often without time for adequate preopera- 
tive study or preparation, because of an immediate 
threat o limb or life. 
A "reconstructive procedure" is an open proce- 
dure that is performed to remove, replace, or bypass 
an obstructive or aneurysmal lesion involving the 
vessel wall and restore pulsati~e flow beyond the in- 
volved segment. This category would include bypass 
grafting, interposition grafting, resection and anasto- 
mosis, endartercctomy, or surgical angioplasty with 
patch graft. 
A "restorative procedure" is one in which the 
obstructing element (oftcn clot or plaque) is re- 
moved or displaced from the lumen of an arterial or 
venous egment, allowing flow through the lumen to 
be restored to normal or near normal without direct 
reconstruction. This is often done through a limited 
and even remote point ofaccess, leaving the involved 
segment basically intact. Examples include throm- 
bcctomy, embolectomy, enzymatic thrombolysis, la- 
ser plaque destruction, atherectomy, and translumi- 
nal balloon dilation. 
Both of the above types of interventions are 
grouped under "revascularization" procedures. In 
contrast, a "nonreconstructive procedure" is any 
procedure that is designed to improve or to protect 
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blood flow without using direct vascular reconstruc- 
tion. Included would be sympathectomy, fas- 
ciotomy, and release of compression of the artery, as 
by division of a band or resection of a rib. "Ablative 
procedures" are those that are designed to remove 
nonviable or diseased material or that interrupt flow 
in patent vessels. These would include major or mi - 
nor amputation, debridement, or removal of an in- 
fected graft. Ligation of an arterial segment is in- 
cluded here although nothing is removed. 
Finally, when the original procedure deteriorates 
or fails and corrective measures are tal~en to restore 
or preserve functional patency, it is important o 
distinguish between revisions and "redo" proce- 
dures, even though both may be called secondary 
reconstructions. In a "revision," there is retention 
without significant modification of all or most of the 
graft or reconstructed segment, as in patch angio- 
plasty. Distal extension from a graft that is or has 
been rendered patent hroughout most of its length 
may also be considered a revision rather than a 
"redo." A "redo" implies replacement orbypass of all 
or most of the graft or reconstructed segment (e.g., 
does not retain at least the majority of the previous 
graft and one ofits anastomoses). 
Grouping and charaeterization of lower ex- 
tremity revascularization procedures. In addition 
to the broad categories defined above, lower extrem- 
ity vascularization procedures can be characterized 
by type of procedure (e.g., endarterectomy, inter- 
position graft, bypass procedure, embolectomy, or 
balloon dilation), location with identification of the 
arterial segment operated on or the proximal and 
distal sites of a bypass graft or endarterectomy, and 
side (e.g., right, left to right, or bilateral). Additional 
specific details, such as graft type, shape, size, type of 
anastomosis, anatomic route of a bypass graft, and 
incisional approach, are worth documenting but may 
create so many variables that innumerable subgroups 
would be required and defy categorization. There- 
fore, there is a need for a more inclusive system of 
grouping, allowing similar procedures to be com- 
pared. The following general groupings are sug- 
gested for lower extremity revascularization proce- 
dures. This system divides procedures according to 
whether they are direct or indirect (extraanatomic or 
ex situ) and whether they deal with occlusive disease 
proximal to, at, or distal to the femoral bifurcation. 
1. Direct (in situ) proximal revascularization: i - 
cludes aortoiliac, iliofemoral, and aortofemoral 
endarterectomy or bypass procedures, unilateral 
or bilateral. 
2. Indirect (ex situ) proximal revascularization: i -
cludes such extraanatomic bypass procedures as 
axillofemoral, crossover femorofemoral, axillob- 
ifemoral, and thoracoaortofemoral. 
3. Direct (in situ)femoral revascularization: from 
external i iac to proximal superficial and profunda 
femoral arteries; includes profundaplasty b end- 
arterectomy and/of  patch angioplasty. 
4. Indirect (ex situ)femoral revascularization: i - 
cludes obturator bypass, axillopopliteal, and 
crossover femoropopliteal bypass procedures. 
5. Distal revascularization: i cludes most infraingui- 
nal bypass procedures, uch as above-knee f mo- 
ropopliteal bypass, below-knee femoropopliteal 
bypass, femorocrural nd femoropedal bypasses, 
above-knee and below-knee popliteocrural and 
above-knee and below-lmee popliteopedal bypass 
and sequential femorodistal bypasses to popliteal, 
crural, or pedal arteries. Differentiation between 
an in situ or ex situ graft course hefe does not 
warrant subcategorization (and may be confusing 
because an in situ vein bypass would actually be an 
ex situ or extraanatomic revascularization). 
COMMENT: When comparing procedures that 
are "competätive" for revascularizing a particular ar- 
terial segment, as in comparing aortobifemoral nd 
axillobifemoral bypass procedures or surveying the 
overall results of surgical management of aortoiliac 
occlusive disease, it is appropriate that such different 
procedures be included in one report. On the other 
hand, when comparing two or more technical or 
treatment variables, such as graft types or antithrom- 
botic drugs, with graft occlusion as the end point, it 
is recommended that broad categories that contain 
multiple operations not be combined. Instead, these 
variables hould be compared on the same or very 
similar procedures. 
The category "femorofemoral bypass grafts" 
should include all similar crossover grafts whether 
the origin is the external i iac artery or the termina- 
tion the profunda femoris artery. Similarly, femoro- 
popliteal and femorocrural grafts should include 
those that also originate on the external i iac, super- 
ficial femoral, or profunda femoris arteries. However, 
the proportion of each different origin and termina- 
tion can and often should be noted. In the important 
instance of above-knee compared with below-lmee 
popliteal termination of a graft, separation i to two 
groups is preferable to simply noting the proportion 
of each and then evaluating them together. Multiple 
added or sequential outflow distal bypass grafts are 
better considered separately and not included with 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 3 Rutherford et al. 535 
Tab le  V I I .  Types o f  compl icat ions w i th  suggested grad ing for outcome and severity 
Complication (type) Severity/outcome* 
Systemic/remote 
Cardiac 
Ectopic/arrhythmia 
Congestive failnre 
Myocardial infarction 
Stroke/TIA 
Deep venous thrombosis 
Suspected 
Confirmed 
Pulmonary embolism 
Suspected 
Confirmed 
Coagulation complications (including drug-induced) 
Spontaneous hemorrhage 
Thrombocytopenia 
"White clot syndrome" 
Thrombosis from ATIII, protein C or S deficiency 
Renal insufficiency 
Contrast media-induced 
Thromboembolic 
Ischemic (acute tubular necrosis) 
Obstructive 
Local/vascular 
Graft infection 
Early (<30)/late (>30 days) 
Culture positive/negative 
Noninvasive (exposed, contaminated) 
Invasive, involves graft or änastomoses 
Complications of graft/vessel interaction 
Intimal hyperplasia (arteriographic, ntraoperative, 
or pathologic diagnosis 
Proximal anastomosis 
Distal anastomosis 
Anastomotic pseudoaneurysm 
Mechanical 
Infectious 
Graft complications (exclusive of anastomotic changes) 
Dilation/aneurysm 
Stenosis, focal/diff-~se 
Elongation/kinldng 
Intrinsic, strnctnral defect'f 
Arteriosclerotic change]" 
Technicall- 
Anastomotic hemorrhage 
External bleeding 
Internal (hematoma) 
1 = little/no hemodynamic consequence 
2 = symptomatic/required treatment 
3 = cardiac arrest/fatal 
1 = TIA/temporary deficit 
2 = permanant deficit 
3 = fatal 
1 = hospitalization not prolonged 
2 = treatment prolonged hospitalization 
3 = required operation 
1 = mild, required antithrombotic drugs 
2 = serious, required resuscitation 
3 = severe, required embolectomy or fatal 
1 = resolving without reatment 
2 = requiring drug therapy 
3 = requiring operation or fatal 
1 = transient, not requiring dialysis 
2 = transient, required ialysis 
3 = permanent (dialysis, transplant, death) 
1 = successful local treatment 
2 = required graft removal/bypass 
3 = loss of limb/life 
1 = òbserved, no treatment required 
2 = local.treatment sutficed (dilation/revision, local resection) 
3 = required "redo" operation 
I = observed, no treatment required 
2 = local treatment sufficed (dilation/revision, local resection) 
3 = required "redo" operation 
1 = observed, no treatment 
2 = local treatment suttäced (dilation/revision, local resection) 
3 = required "redo" operation 
1 = observed 
2 = required aspiration, drainage 
3 = required anastomotic repair, revision 
*0 =none; 1 = mild; 2 = moderate; 3 = severe. 
}These feamres apply to all subgroups of graft complications exclusive of anastomotic changes. 
:~See Criteria for Significant Change in Status, p. 522. 
e i ther  femoropop l i tea l  or  femorocrura l  bypass grafts 
(some reports have inc luded each l imb in each o f  
these two categories).  Patency rates o f  these and 
o ther  mul t ip le  - te rminat ion  grafts (e. g., aor tob i femo - 
ral, axi l lobi femoral ,  above-knee femoral -popl i tea l -  
tibial) shou ld  be calculated by cons ider ing each graft 
l imb separately. 
REPORTING DEATHS AND 
COMPL ICAT IONS 
Postoperat ive deaths may be a result  o fphys ic ian  
errors (in diagnosis,  techn ique ,  judgement ,  or  man-  
agement )  or, in their  absence, to the disease o f  the 
patient.  Late deaths are usually at t r ibuted to e i ther  
the under ly ing  disease, delayed compl icat ions  o fsur -  
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Tab le  V I I .  Cont 'd  
Complication (type) Severity~outcome * 
Local/vascular cont'd. 
Graft thrombosis 
Early/late 
Cause found 
Cause not found 
Unsatisfactory hemodynamic result (despite patency) 
Insufficient inflow 
Insufficient outflow 
"Steal" 
Graft-enteric reaction 
Anastomotic (fistula) vs. nonanastomotic (erosion) 
Primary infectious cause vs. no secondary infection 
Unexpected tissue loss/amputation 
Atherothromboembolism 
Colon ischemia 
Spinal cord ischemia 
Local/nonvascular 
Noninfectious wound fluid accumulations 
Hematoma 
Seroma 
Lymphocele 
Wound infections 
Superficial 
Deep 
Exposed/contaminated graft 
Lymphatic disruption 
Lymphedema 
Lymphocele 
Lymph fistula 
Ureteral injury 
Complete obstruction 
Partial obstruction 
Urinoma (closed leak) 
Urinary fistula 
Sexual dysfunction •
Affecting ejaculation (e.g., retrograde) 
Affecting fertility 
Affecting erection (potency) 
Complications of sympathectomy 
Disturbance in ejaculation/potency 
Neuralgia fter sympathectomy 
No demonstrable therapeutic benefit 
1 = not corrected or corrected with restorative procedure 
2 = required revision or "redo" 
3 = limb loss (unexpected tissue loss) 
1 = > + 1 (but less than expected)~ 
2= + 1:~ 
3=<+1:~ 
1 = successfully treated without permanant sequelae 
2 = permanant sequelae (e.g., limb loss, -ostomy) 
3 = fatal outcome 
1 = minor tissue w/o amputation 
2 = mhaor amputation 
3 = major amputation 
1 = without issue loss 
2 = with minor tissue loss/amputation 
3 = with major tissue loss/amputation 
1 = not requiring operation 
2 = colon resection or colostomy 
3 = fatal 
1 = transient 
2 = minor permanent deficit 
3 = major permanent deficit 
1 = observed, resolved 
2 = aspirated 
3 = surgical drainage 
1 = treated with antibiotic 
2 = treated with drainage 
3 = required graft removal or bypass 
1 = no treatment required 
2 = aspiration, drainage 
3 = exploration with closure of lymphatics 
1 = resolved spontaneously 
2 = required rainage, diversion 
3 = surgical correction or nephrectomy required 
1 = mild or no effect on sexual activity 
2 = reduces exual activity 
3 = prevents or eliminates sexual activity 
gical management ,  or  are cons idered "unre la ted . "  
Both  early (less than  30 days) and late (more  than  
30 days) deaths  that  occur  after lower  ext remi ty  
revascu lar i zat ion  procedures  shou ld  be repor ted  to 
give a t ruer  perspect ive ,  and the  add i t iona l  break-  
down of fered ear l ier  for late deaths  is recom-  
mended.  
Compl icat ions  o f  lower  extremity  procedures  can 
be e i ther  specific or  nonspecif ic ,  but  the separat ion 
between the two is o f ten indist inct.  The  nonspecif ic  
category includes such prob lems as atelectasis, dehis- 
cence,  and congest ive heart  failure as wel l  as some 
that,  a l though not  specifically related to operat ive 
techn ique ,  are nevertheless indirect ly related to the 
procedure  or  to the under ly ing disease it treats. Ex- 
amples are myocardia l  infarct ion,  stroke, deep ve- 
nous thrombos is ,  and pu lmonary  embol i sm.  Even 
such universal compl icat ions as wound infect ion and 
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hemorrhage may be relatable to specific aspects of 
the patient's disease. Bypass grafting in the face of a 
septic foot or open tflcer will increase the chance of  
wound and graff infection, and the use of heparin or 
other antithrombotic drugs will increase the chance 
of wound hemorrhage. Therefore, it is suggested 
that complicafions that are specific to the operation 
or the underlying disease be reported. They fall into 
local vascular, local nonvascular, and remote systemic 
categories. In the case of some reported complica- 
tions, it may be appropriate to separate further those 
that occur early in the postoperative period from 
those that develop later, with 30 days after operation 
used as the arbitrary dividing point. 
Many complications are difficult to grade in terms 
of severity other than to identify them as causing 
death, causing permanent disability, necessitating re- 
operation, prolonging hospital stay, or otherwise, as 
"insignificant." Table VII lists types of  complica- 
tions, with a breakdown into subtypes that might be 
valuable to consider in reports on lower extremity 
revascularization, as weil as suggested grading for 
outcome or severity. 
F INAL COMMENT 
These standardized reporting practices are rec- 
ommended primarily to allow clinical studies on var- 
ious aspects of the management of lower limb isch- 
emia to be read with confidence and compared with 
validity. They are still in evolution and, as this new 
version arrests, will require periodic revision. It is 
further hoped that the grading schemes and outcome 
criteria featured here will be incorporated into clini- 
cal databases and provide a common foundation, in 
the form of disease severity scoring, 39 for valid out- 
come comparisons. 
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